Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Do Hedge Funds Love Applied Genetic Technologies Corp (AGTC)?

Page 1 of 2

It is already common knowledge that individual investors do not usually have the necessary resources and abilities to properly research an investment opportunity. As a result, most investors pick their illusory “winners” by making a superficial analysis and research that leads to poor performance on aggregate. The Standard and Poor’s 500 Index returned 5.2% over the 12-month period ending October 30, while more than 51% of the constituents of the index underperformed the benchmark. Hence, a random stock picking process will most likely lead to disappointment. At the same time, the 30 most favored S&P 500 stocks by the hedge funds monitored by Insider Monkey (as of September 2014) generated a return of 9.5% over the same time span, with 63% of these stocks outperforming the benchmark. Of course, hedge funds do make wrong bets on some occasions and these get disproportionately publicized on financial media, but piggybacking their moves can beat the broader market on average. That’s why we are going to go over recent hedge fund activity in Applied Genetic Technologies Corp (NASDAQ:AGTC).

Applied Genetic Technologies Corp (NASDAQ:AGTC) investors should pay attention to a decrease in activity from the world’s largest hedge funds lately. AGTC was in 11 hedge funds’ portfolios at the end of the third quarter of 2015. There were 12 hedge funds in our database with AGTC positions at the end of the previous quarter. At the end of this article we will also compare AGTC to other stocks, including Cascade Microtech, Inc. (NASDAQ:CSCD), Franklin Financial Network Inc (NYSE:FSB), and DURECT Corporation (NASDAQ:DRRX) to get a better sense of its popularity.

Follow Applied Genetic Technologies Corp (NASDAQ:AGTC)
Trade (NASDAQ:AGTC) Now!

In the eyes of most shareholders, hedge funds are perceived as unimportant, outdated financial vehicles of the past. While there are more than 8000 funds trading today, Our researchers hone in on the masters of this group, around 700 funds. These hedge fund managers watch over the lion’s share of all hedge funds’ total asset base, and by following their top picks, Insider Monkey has determined a few investment strategies that have historically beaten Mr. Market. Insider Monkey’s small-cap hedge fund strategy outrun the S&P 500 index by 12 percentage points per year for a decade in their back tests.

Keeping this in mind, we’re going to go over the latest action regarding Applied Genetic Technologies Corp (NASDAQ:AGTC).

How are hedge funds trading Applied Genetic Technologies Corp (NASDAQ:AGTC)?

Heading into Q4, a total of 11 of the hedge funds tracked by Insider Monkey were long this stock, a change of -8% from the second quarter. With hedgies’ sentiment swirling, there exists an “upper tier” of key hedge fund managers who were increasing their holdings significantly (or already accumulated large positions).

Of the funds tracked by Insider Monkey, Point72 Asset Management, managed by Steve Cohen, holds the most valuable position in Applied Genetic Technologies Corp (NASDAQ:AGTC). Point72 Asset Management has an $13.1 million position in the stock, comprising 0.1% of its 13F portfolio. On Point72 Asset Management’s heels is Visium Asset Management, led by Jacob Gottlieb, holding an $12.4 million position; the fund has 0.2% of its 13F portfolio invested in the stock. Some other peers with similar optimism include Joseph Edelman’s Perceptive Advisors, Israel Englander’s Millennium Management and Nathan Fischel’s DAFNA Capital Management.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!